Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicentre Phase II Clinical Study of Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

NCT06570317 is registered in ClinicalTrials.gov with Second Hospital of Shanxi Medical University as lead sponsor.

NCT NCT06570317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicentre Phase II Clinical Study of Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC
Lead sponsor
Second Hospital of Shanxi Medical University
Phase
Observational
Overall status
Recruiting
Start date
August 24, 2024
Completion date
June 30, 2026
Enrollment
40 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nintedanib, nsclc, radiation pneumonitis